Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination ta

Memento’s lead asset is a bispecific antibody that blocks VEGF and activates Tie2. The biotech plans to test the candidate in retinal conditions such as neovascular age-related macular degeneration and diabetic macular edema. Memento Medicines has bagged $93 million in series A proceeds, which the Boston biotech plans to funnel toward a newly licensed asset for retinal disorders. In conjunction with the funding round, Memento struck up an exclusive deal with MabTics and Curacle, paying unspecif

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing appr

Kovina Therapeutics Inc. today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of research validating its HPV E6 targeted therapeutic approach. The publication, “Covalent Inhibitors of Human Papillomavirus Type 16 E6 Protein Restore p53 Function and Suppress Growth of HPV-Driven Tumors in vivo,” reports that small molecules developed through Kovina’s HPV E6 program restore p53 tumor suppressor activity, induce apoptosis and senescence in HPV-positive cancer c

Teva Pharmaceutical Industries (NYSE: TEVA) has submitted a New Drug Application (NDA) to the US FDA for ecopipam, an investigational selective dopamine D1 receptor antagonist, seeking approval for the treatment of pediatric Tourette syndrome. If approved, ecopipam would represent the first new FDA-authorized therapy for pediatric tic disorder in more than a decade and the first agent in clinical use to target the D1 receptor subtype in this indication. The filing arrives weeks after Teva closed

Phase 1b data establish first clinical evidence of human translation of an AMPK Network Activator, with statistically significant improvements in liver fat, visceral adipose tissue, triglycerides, adiponectin, and resting metabolic rate in adults with obesity and prediabetes、 Overall tolerability pro to placebo. No adverse events related to core body temperature, flushing, or heart rate Companion mechanistic poster confirms ATX-304 activates AMPK without decreasing cellular ATP levels, disting

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation June 19, 2026 -- Kither Biotech Pty Ltd and Kither Biotech srl, a clinical-stage biop

A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.Researchers in Spain and Switzerland have identified an experimental molecule that may help restore the brain's natural defenses against Alzheimer's disease. The compound, known as OLE, appears to "reprogram" microglia, the brain's immune cells, allowing them to

June 20, 2026 -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a critical step toward the New Drug Application (NDA) submission in the United States and brings new hope to millions of patients with cardiovascular and cerebrovascular diseases worldwide. Evategrel (CG-0255) is the leading asset developed f

June 22, 2026 -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervou